Neurotrophin dysregulation by tau-mediated pathways seems to be commonly identified in various neurodegenerative disorders; nevertheless, in some studies, the nerve growth factor (NGF) binding site density was noticeably lower in PSP, but not in other parkinsonian syndromes [22]. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.